Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $243,653 - $308,616
16,700 New
16,700 $254,000
Q4 2023

Feb 14, 2024

SELL
$13.43 - $19.63 $3.25 Million - $4.75 Million
-241,879 Reduced 88.13%
32,569 $622,000
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $3.17 Million - $4.12 Million
186,862 Added 213.35%
274,448 $5.57 Million
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $861,217 - $1.25 Million
53,961 Added 160.48%
87,586 $1.6 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $345,281 - $625,889
17,527 Added 108.88%
33,625 $695,000
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $2.05 Million - $2.66 Million
-88,417 Reduced 84.6%
16,098 $421,000
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $48,571 - $106,360
2,819 Added 2.77%
104,515 $2.65 Million
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $2.44 Million - $3.53 Million
84,281 Added 483.96%
101,696 $3.21 Million
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $546,482 - $844,105
17,415 New
17,415 $705,000
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $693,260 - $1.09 Million
-30,473 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$26.16 - $41.39 $1.39 Million - $2.19 Million
-52,975 Reduced 63.48%
30,473 $856,000
Q4 2020

Feb 16, 2021

SELL
$17.0 - $32.36 $539,155 - $1.03 Million
-31,715 Reduced 27.54%
83,448 $2.17 Million
Q3 2020

Nov 16, 2020

SELL
$17.14 - $25.47 $765,061 - $1.14 Million
-44,636 Reduced 27.93%
115,163 $1.97 Million
Q2 2020

Aug 14, 2020

BUY
$13.97 - $36.56 $2.23 Million - $5.84 Million
159,799 New
159,799 $3.95 Million
Q1 2020

May 15, 2020

SELL
$8.78 - $19.28 $209,938 - $461,004
-23,911 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$7.33 - $10.79 $175,267 - $257,999
23,911 New
23,911 $242,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.01B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.